Endo unit launches generic version of Merck blockbuster

An Endo International operating company this week launched the first generic version Merck ’s multibillion-dollar, cholesterol-lowering medicine Zetia. North Jersey-based Par Pharmaceuticals, which Endo (NASDAQ: ENDP) acquired last year for $8 billion, is the marketer and distributor of the product in the United States. Endo, based in Dublin, Ireland, has its U.S. headquarters in Malve rn. Endo eliminates 375 sales jobs According to data from IMS Health, U.S. sales of Zetia were about $2.6 billion…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news